
Sabine Grimm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3437178/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2022, 40, 509-518.	3.3	1
2	Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2021, 39, 171-180.	3.3	4
3	Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to "TRUST4RD: tool for reducing uncertainties in the evidence generation for) Tj	ETQq2.7 0.7	84 3 :14 rgBT
4	High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation. Health Technology Assessment, 2021, 25, 1-276.	2.8	16
5	State of the ART? Two New Tools for Risk Communication in Health Technology Assessments. Pharmacoeconomics, 2021, 39, 1185-1196.	3.3	4
6	Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study. Value in Health, 2021, 24, 983-994.	0.3	7
7	Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2021, 39, 1397-1410.	3.3	3
8	Implementation Barriers to Value of Information Analysis in Health Technology Decision Making: Results From a Process Evaluation. Value in Health, 2021, 24, 1126-1136.	0.3	4
9	Optimizing the Use of High-Sensitivity Troponin Assays for the Early Rule-out of Myocardial Infarction in Patients Presenting with Chest Pain: A Systematic Review. Clinical Chemistry, 2021, 67, 237-244.	3.2	17
10	Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models. Pharmacoeconomics, 2020, 38, 205-216.	3.3	23
11	Cost assessment of health interventions and diseases. RMD Open, 2020, 6, e001287.	3.8	11
12	Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis. Radiology, 2020, 297, 40-48.	7.3	15
13	Health technology assessment: a framework. RMD Open, 2020, 6, e001289.	3.8	17
14	Steps in implementing a health economic evaluation. RMD Open, 2020, 6, e001288.	3.8	5
15	Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?. RMD Open, 2020, 6, .	3.8	1
16	Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment. Annals of Clinical Biochemistry, 2019, 56, 72-81.	1.6	1
17	Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 1195-1207.	3.3	8
18	Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 887-894.	3.3	13

SABINE GRIMM

#	Article	IF	CITATIONS
19	Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 655-667.	3.3	8
20	Estimating Future Health Technology Diffusion Using Expert Beliefs Calibrated to an Established Diffusion Model. Value in Health, 2018, 21, 944-950.	0.3	11
21	EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. Value in Health, 2018, 21, 49-56.	0.3	71
22	EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Applied Health Economics and Health Policy, 2018, 16, 429-432.	2.1	12
23	Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2018, 22, 1-264.	2.8	106
24	Assessing the Expected Value of Research Studies in Reducing Uncertainty and Improving Implementation Dynamics. Medical Decision Making, 2017, 37, 523-533.	2.4	17
25	The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. Pharmacoeconomics, 2017, 35, 1287-1296.	3.3	38
26	When Future Change Matters: Modeling Future Price and Diffusion in Health Technology Assessments of Medical Devices. Value in Health, 2016, 19, 720-726.	0.3	11